Antipsychotic drugs and QT interval prolongation

被引:83
|
作者
Zareba, W [1 ]
Lin, DA [1 ]
机构
[1] Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med,Cardiol Unit, Rochester, NY 14642 USA
关键词
QTc prolongation; antipsychotic drugs; torsades de pointes;
D O I
10.1023/A:1024122706337
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The QTc prolongation by antipsychotic drugs is of major concern, especially in light of the data indicating an increased risk of sudden death in psychiatric patients taking these drugs. Sudden death in psychiatric patients could be partially attributed to drug-induced torsades de pointes and for this reason careful evaluation of QTc prolonging properties of antipsychotic drugs is needed. Antipsychotic drugs prolong QT interval usually by blocking the potassium I-Kr current. Improved understanding of ion channel structure and kinetics and its role in repolarization has tremendous impact on understanding of the mechanisms of drug-induced QT prolongation and torsades de pointes. Proarrhythmia caused by a QT-prolonging drug occurs infrequently, and usually multiple factors need to operate to precipitate such an event including a combination of two or more drugs affecting the same pathway, hypokalemia, and possibly genetic predisposition. Currently prescribed antipsychotics might cause QT prolongation ranging from 4-6 ms for haloperidol and olanzapine to 35 ms for thioridazine. The response of a patient to a drug is very individual and therefore an individualized system of drug administration and monitoring needs to be developed which takes into account baseline QTc duration and its changes after a drug was introduced. A systematic approach while stratifying psychiatric patients as those with short QTc (QTc less than or equal to 0.41 sec), borderline QTc QTC = 0.42-0.44 sec), and prolonged QTc (0.45 sec) is being proposed to improve the safety of administering antipsychotic drugs and to decrease the risk of drug-related sudden death in psychiatric patients.
引用
收藏
页码:291 / 306
页数:16
相关论文
共 50 条
  • [21] PROLONGATION OF THE QT INTERVAL BY KETANSERIN
    CAMERON, HA
    WALLER, PC
    RAMSAY, LE
    POSTGRADUATE MEDICAL JOURNAL, 1988, 64 (748) : 112 - 117
  • [22] EXPERIMENTAL QT INTERVAL PROLONGATION
    MALFATTO, G
    STEINBERG, SF
    ROSEN, TS
    DANILO, P
    ROSEN, MR
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1992, 644 : 74 - 83
  • [23] Rivastigmine and QT interval prolongation
    Inglis, F
    BRITISH JOURNAL OF PSYCHIATRY, 2003, 182 : 549 - 550
  • [24] The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
    Giraud, Eline L.
    Ferrier, Kaylee R. M.
    Lankheet, Nienke A. G.
    Desar, Ingrid M. E.
    Steeghs, Neeltje
    Beukema, Rypko J.
    van Erp, Nielka P.
    Smolders, Elise J.
    LANCET ONCOLOGY, 2022, 23 (09): : E406 - E415
  • [25] QT interval prolongation and beyond
    Couderc, Jean-Philippe
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2006, 11 (04) : 287 - 288
  • [26] SYNCOPE AND QT INTERVAL PROLONGATION
    MEZGER, J
    ETTINGER, U
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1990, 132 (46): : 730 - 731
  • [27] Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
    Bugarski-Kirola, Dragana
    Nunez, Rene
    Odetalla, Ramzey
    Liu, I-Yuan
    Turner, Mary Ellen
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [28] QT PRODACT: Database construction for the evaluation of the risk of QT interval prolongation by drugs in Japan - Foreword
    Nakaya, H
    Hashimoto, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 99 (05) : 421 - 421
  • [29] Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders
    Aronow, Wilbert S.
    Shamliyan, Tatyana A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [30] Aging effects on QT interval:Implications for cardiac safety of antipsychotic drugs
    Simon W.Rabkin
    Journal of Geriatric Cardiology, 2014, 11 (01) : 20 - 25